1 Siscovick DS, Barringer TA, Fretts AM, et al. Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association. Circulation 2017;135:e867-e84.
2 Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol 2014;11:276-89.
3 Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113:898-918.
4 Borghi C, Omboni S, Reggiardo G,et al. Efficacy of Zofenopril Compared With Placebo and Other Angiotensin-converting Enzyme Inhibitors in Patients With Acute Myocardial Infarction and Previous Cardiovascular Risk Factors: A Pooled Individual Data Analysis of 4 Randomized, Double-blind, Controlled, Prospective Studies. J Cardiovasc Pharmacol 2017;69:48-54.
5 Menendez ME, Memtsoudis SG, Opperer M, et al. A nationwide analysis of risk factors for in-hospital myocardial infarction after total joint arthroplasty. Int Orthop 2015;39:777-86.
6 Braunwald E. Treatment of Left Main Coronary Artery Disease. N Engl J Med 2016;375:2284-5.
7 Bangalore S, Guo Y, Samadashvili Z, et al. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. N Engl J Med 2015;372:1213-22.
8 Hausenloy DJ, Candilio L, Evans R, et al. Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. N Engl J Med 2015;373:1408-17.
9 Guo Y, Cao S, Hu S, et al. Effect of milrinone on short-term outcome of patients with myocardial dysfunction undergoing coronary artery bypass graft. Chin Heart J 2014; 26: 572-4.
10 Aldea GS, Bakaeen FG, Pal J, et al. The Society of Thoracic Surgeons Clinical Practice Guidelines on Arterial Conduits for Coronary Artery Bypass Grafting. Ann Thorac Surg 2016;101:801-09.
11 Shafarenko MS, Catapano J, Luo S, et al. Outcomes following coronary artery bypass grafting with microsurgery in paediatric patients. Interact Cardiovasc Thorac Surg 2018;27:27-33.
12 Amin S, Werner RS, Madsen PL, et al. Influence of external stenting on venous graft flow parameters in coronary artery bypass grafting: a randomized study. Interact Cardiovasc Thorac Surg 2018;26:926-31.
13 Gordon JB, Daniels LB, Kahn AM, et al. The Spectrum of Cardiovascular Lesions Requiring Intervention in Adults After Kawasaki Disease. JACC Cardiovasc Interv 2016;9:687-96.
14 Laukkanen JA, Kunutsor SK, Niemela M, et al. All-cause mortality and major cardiovascular outcomes comparing percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: a meta-analysis of short-term and long-term randomised trials. Open Heart 2017;4:e000638.
15 Badheka AO, Panaich SS, Arora S, et al. Percutaneous Coronary Intervention: Relationship Between Procedural Volume and Outcomes. Curr Cardiol Rep 2016;18:39.
16 Hannan EL, Farrell LS, Walford G, et al. Utilization of radial artery access for percutaneous coronary intervention for ST-segment elevation myocardial infarction in New York. JACC Cardiovasc Interv 2014;7:276-83.
17 Hye RJ, Voeks JH, Malas MB, et al. Anesthetic type and risk of myocardial infarction after carotid endarterectomy in the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST). J Vasc Surg 2016;64:3-8 e1.
18 Yamanaka T, Kawai Y, Miyoshi T, et al. Remote ischemic preconditioning reduces contrast-induced acute kidney injury in patients with ST-elevation myocardial infarction: a randomized controlled trial. Int J Cardiol 2015;178:136-41.
19 Nishizawa K, Yano T, Tanno M, et al. Chronic Treatment With an Erythropoietin Receptor Ligand Prevents Chronic Kidney Disease-Induced Enlargement of Myocardial Infarct Size. Hypertension 2016;68:697-706.
20 Lee WC, Fang HY, Chen HC, et al. Anemia: A significant cardiovascular mortality risk after ST-segment elevation myocardial infarction complicated by the comorbidities of hypertension and kidney disease. PLoS One 2017;12:e0180165.
21 Hansen MK, Gammelager H, Jacobsen CJ, et al. Acute Kidney Injury and Long-term Risk of Cardiovascular Events After Cardiac Surgery: A Population-Based Cohort Study. J Cardiothorac Vasc Anesth 2015;29:617-25.
22 Nojiri T, Yamamoto K, Maeda H, et al. A Double-Blind Placebo-Controlled Study of the Effects of Olprinone, a Specific Phosphodiesterase III Inhibitor, for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer. Chest 2015;148:1285-92.
23 Brown DG, Wilkerson EC, Love WE. A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons. J Am Acad Dermatol 2015;72:524-34.
24 Karibe H, Hayashi T, Narisawa A, et al. Clinical Characteristics and Outcome in Elderly Patients with Traumatic Brain Injury: For Establishment of Management Strategy. Neurol Med Chir (Tokyo) 2017;57:418-25.
25 Harrison SA, Chang ML, Beavo JA. Differential inhibition of cardiac cyclic nucleotide phosphodiesterase isozymes by cardiotonic drugs. Circulation 1986;73:III109-16.
26 Shipley JB, Tolman D, Hastillo A, et al. Milrinone: basic and clinical pharmacology and acute and chronic management. Am J Med Sci 1996;311:286-91.
27 Endoh M, Yamashita S, Taira N. Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle. J Pharmacol Exp Ther 1982;221:775-83.
28 Endoh M, Yanagisawa T, Taira N, et al. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle. Circulation 1986;73:III117-33.
29 Levy JH, Bailey JM, Deeb GM. Intravenous milrinone in cardiac surgery. Ann Thorac Surg 2002;73:325-30.
30 Chen EP, Bittner HB, Davis RD, Jr., Van Trigt P, 3rd. Milrinone improves pulmonary hemodynamics and right ventricular function in chronic pulmonary hypertension. Ann Thorac Surg 1997;63:814-21.
31 Kwak YL, Oh YJ, Shinn HK, et al. Haemodynamic effects of a milrinone infusion without a bolus in patients undergoing off-pump coronary artery bypass graft surgery. Anaesthesia 2004;59:324-31.
32 Lee JH, Oh YJ, Shim YH, et al. The effect of milrinone on the right ventricular function in patients with reduced right ventricular function undergoing off-pump coronary artery bypass graft surgery. J Korean Med Sci 2006;21:854-58.
33 McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-69.
34 Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:1810-52.
35 Zangrillo A, Biondi-Zoccai G, Ponschab M, et al. Milrinone and mortality in adult cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2012;26:70-7.
36 Majure DT, Greco T, Greco M, et al. Meta-analysis of randomized trials of effect of milrinone on mortality in cardiac surgery: an update. J Cardiothorac Vasc Anesth 2013;27:220-9.
37 Tang X, Liu P, Li R,et al. Milrinone for the Treatment of Acute Heart Failure After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis. Basic Clin Pharmacol Toxicol 2015;117:186-94.
38 Koperny M, Lesniak W, Jankowski M, et al. The Cochrane collaboration - the role in the evolution of evidence-based medicine and development of cooperation in Poland. Przegl Epidemiol 2016;70:508-20.
39 Arbeus M, Axelsson B, Friberg O, et al. Milrinone increases flow in coronary artery bypass grafts after cardiopulmonary bypass: a prospective, randomized, double-blind, placebo-controlled study. J Cardiothorac Vasc Anesth 2009;23:48-53.
40 Couture P, Denault AY, Pellerin M, et al. Milrinone enhances systolic, but not diastolic function during coronary artery bypass grafting surgery. Can J Anaesth 2007;54:509-22.
41 Doolan LA, Jones EF, Kalman J, et al. A placebo-controlled trial verifying the efficacy of milrinone in weaning high-risk patients from cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997;11:37-41.
42 Hadadzadeh M, Hosseini SH, Mostafavi Pour Manshadi SM, et al. Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Med Iran 2013;51:681-6.
43 Hamada Y, Kawachi K, Yamamoto T, Nakata T, Kashu Y, Sato M, Watanabe Y. Effects of single administration of a phosphodiesterase III inhibitor during cardiopulmonary bypass: comparison of milrinone and amrinone. Jpn Circ J 1999;63:605-609.
44 Hayashida N, Tomoeda H, Oda T, et al. Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass. Ann Thorac Surg 1999;68:1661-7.
45 Jebeli M, Ghazinoor M, Mandegar MH, et al. Effect of milrinone on short-term outcome of patients with myocardial dysfunction undergoing coronary artery bypass graft: A randomized controlled trial. Cardiol J 2010;17:73-8.
46 Jo HR, Lee WK, Kim YH, et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean J Anesthesiol 2010;59:92-8.
47 Kwak YL, Oh YJ, Kim SH, et al. Efficacy of pre-emptive milrinone in off-pump coronary artery bypass surgery: comparison between patients with a low and normal pre-graft cardiac index. Eur J Cardiothorac Surg 2004;26:687-93.
48 Mollhoff T, Loick HM, Van Aken H, et al. Milrinone modulates endotoxemia, systemic inflammation, and subsequent acute phase response after cardiopulmonary bypass (CPB). Anesthesiology 1999;90:72-80.
49 Shi Y, Denault AY, Couture P, et al. Biventricular diastolic filling patterns after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2006;131:1080-6.
50 Song JW, Jo YY, Jun NH, et al. The effect of milrinone on the intraoperative hemodynamics during off-pump coronary bypass surgery in patients with an elevated echocardiographic index of the ventricular filling pressure. Korean J Anesthesiol 2011;60:185-91.
51 Yamaguchi A, Tanaka M, Naito K, et al. The efficacy of intravenous milrinone in left ventricular restoration. Ann Thorac Cardiovasc Surg 2009;15:233-8.
52 Yamaura K, Okamoto H, Akiyoshi K, et al. Effect of low-dose milrinone on gastric intramucosal pH and systemic inflammation after hypothermic cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2001;15:197-203.
53 Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1545-1602.
54 Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1459-544.
55 Moran AE, Forouzanfar MH, Roth GA, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study. Circulation 2014;129:1483-92.
56 Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation 2014;129:1493-501.
57 Aguilar-Palacio I, Malo S, Feja C, et al. Risk factors control for primary prevention of cardiovascular disease in men: Evidence from the Aragon Workers Health Study (AWHS). PLoS One 2018;13:e0193541.
58 Mehta PK, Wei J, Wenger NK. Ischemic heart disease in women: a focus on risk factors. Trends Cardiovasc Med 2015;25:140-51.
59 Charlson FJ, Moran AE, Freedman G, et al. The contribution of major depression to the global burden of ischemic heart disease: a comparative risk assessment. BMC Med 2013;11:250.
60 Kivimaki M, Nyberg ST, Batty GD, et al. Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data. Lancet 2012;380:1491-97.
61 Ambrose JA, Singh M. Pathophysiology of coronary artery disease leading to acute coronary syndromes. F1000Prime Rep 2015;7:08.
62 Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Thorac Cardiovasc Surg 2015;149:e5-23.
63 Anguita M, Comin J, Almenar L, et al. Comments on the ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. Rev Esp Cardiol (Engl Ed) 2012;65:874-8.
64 McGill HC, Jr., McMahan CA, Gidding SS. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Circulation 2008;117:1216-27.
65 McNeal CJ, Dajani T, Wilson D, et al. Hypercholesterolemia in youth: opportunities and obstacles to prevent premature atherosclerotic cardiovascular disease. Curr Atheroscler Rep 2010;12:20-8.
66 Naci H, Ioannidis JP. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ 2013;347:f5577.
67 Kyu HH, Bachman VF, Alexander LT, et al. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. BMJ 2016;354:i3857.
68 Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003;107:3109-16.
69 Gutierrez J, Ramirez G, Rundek T, et al. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med 2012;172:909-19.
70 Ohman EM. CLINICAL PRACTICE. Chronic Stable Angina. N Engl J Med 2016;374:1167-76.
71 Sipahi I, Akay MH, Dagdelen S, et al. Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era. JAMA Intern Med 2014;174:223-230.
72 Stergiopoulos K, Boden WE, Hartigan P, et al. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med 2014;174:232-40.
73 Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366-74.
74 Head SJ, da Costa BR, Beumer B, et al. Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. Eur J Cardiothorac Surg 2017;52:206-17.
75 Gasz B. The influence of healthcare policy on the outcome parameters of myocardial revascularization procedures as opposed to geographical differences. Eur J Cardiothorac Surg 2018;54:196.
76 Byrne JG, Leacche M. Off-Pump CABG Surgery "No-Touch" Technique to Reduce Adverse Neurological Outcomes. J Am Coll Cardiol 2017;69:937-8.
77 Karkhanis R, Tam DY, Fremes SE. Management of patients with end-stage renal disease: coronary artery bypass graft surgery versus percutaneous coronary intervention. Curr Opin Cardiol 2018;33:546-50.
78 Ohno K, Kuno A, Murase H, et al. Diabetes increases the susceptibility to acute kidney injury after myocardial infarction through augmented activation of renal Toll-like receptors in rats. Am J Physiol Heart Circ Physiol 2017;313:H1130-42.
79 Movsesian M, Ahmad F, Hirsch E. Functions of PDE3 Isoforms in Cardiac Muscle. J Cardiovasc Dev Dis 2018;5.
80 Madeira M, Caetano F, Almeida I, et al. Inotropes and cardiorenal syndrome in acute heart failure - A retrospective comparative analysis. Rev Port Cardiol 2017;36:619-25.
81 Gao B, Qu Y, Sutherland W, et al. Decreased contractility and altered responses to inotropic agents in myocytes from tachypacing-induced heart failure canines. J Pharmacol Toxicol Methods 2018;93:98-107.
82 Parissis JT, Farmakis D, Nieminen M. Classical inotropes and new cardiac enhancers. Heart Fail Rev 2007;12:149-56.
83 Kikura M, Sato S. Effects of preemptive therapy with milrinone or amrinone on perioperative platelet function and haemostasis in patients undergoing coronary bypass grafting. Platelets 2003;14:277-82.
84 Heringlake M, Wernerus M, Grunefeld J, et al. The metabolic and renal effects of adrenaline and milrinone in patients with myocardial dysfunction after coronary artery bypass grafting. Crit Care 2007;11:R51.
85 Metra M, Eichhorn E, Abraham WT, et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J 2009;30:3015-26.
86 Bayram M, De Luca L, Massie MB, et al. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 2005;96:47G-58G.
87 Mebazaa A, Parissis J, Porcher R, et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med 2011;37:290-301.
88 Lee J, Kim WH, Ryu HG, et al. Stroke Volume Variation-Guided Versus Central Venous Pressure-Guided Low Central Venous Pressure With Milrinone During Living Donor Hepatectomy: A Randomized Double-Blinded Clinical Trial. Anesth Analg 2017;125:423-30.
89 Movsesian M, Stehlik J, Vandeput F, et al. Phosphodiesterase inhibition in heart failure. Heart Fail Rev 2009;14:255-63.
90 Belletti A, Castro ML, Silvetti S, et al. The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. Br J Anaesth 2015;115:656-75.
91 Koster G, Bekema HJ, Wetterslev J, et al. Milrinone for cardiac dysfunction in critically ill adult patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med 2016;42:1322-35.